Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Jul 12 2022

• By Malcolm Spicer

• Source: Shutterstock

Related Content

HRA Raising Game To Promote UK OTC Daily Contraceptive, Hopes US Switch Will Follow

Aug 24 2021

HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

Jul 09 2021

Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC

Jun 24 2022

Survey Shows US Voters Have Message For FDA And Congress About OTC Birth Control

Jul 06 2022

Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising

Mar 21 2022

Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study

Jun 21 2018

Related Companies

Perrigo Company PLC

Additional Topics

International United States France Europe Ireland United Kingdom US States FDA Prescription To OTC Switch Drug Approval Standards Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Consumer Drug Review Drug Safety E-Commerce Ingredients Legislation Legal Issues Manufacturing OTC Drugs Policy Politics Regulation Retail Safety Gynecology & Urology

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.